NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Forecast, Price & News $1.57 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$1.50▼$1.5750-Day Range N/A52-Week Range$0.83▼$4.92Volume1,879 shsAverage Volume9,360 shsMarket Capitalization$56.76 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesShort InterestSocial Media Armata Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside345.9% Upside$7.00 Price TargetShort InterestHealthy0.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.32) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Armata Pharmaceuticals has a forecasted upside of 345.9% from its current price of $1.57.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.20% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently decreased by 41.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARMP. Previous Next 2.1 News and Social Media Coverage News SentimentArmata Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders80.10% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.76% of the stock of Armata Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.32) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArmata Pharmaceuticals has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Armata Pharmaceuticals (NYSEAMERICAN:ARMP) StockArmata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.Read More Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARMP Stock News HeadlinesMay 31, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage TherapyMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Armata Pharmaceuticals (ARMP) Buy RecommendationJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 12, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate UpdateMay 11, 2023 | seekingalpha.comArmata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79MMay 11, 2023 | finance.yahoo.comArmata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate UpdateMay 9, 2023 | americanbankingnews.comArmata Pharmaceuticals (ARMP) Set to Announce Earnings on WednesdayJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 9, 2023 | americanbankingnews.comArmata Pharmaceuticals (ARMP) Scheduled to Post Quarterly Earnings on WednesdayApril 6, 2023 | uk.finance.yahoo.comArmata Pharmaceuticals, Inc. (ARMP)March 21, 2023 | americanbankingnews.comArmata Pharmaceuticals, Inc. to Post Q1 2023 Earnings of ($0.29) Per Share, HC Wainwright Forecasts (NYSEAMERICAN:ARMP)March 17, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate UpdateMarch 16, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate UpdateMarch 6, 2023 | marketwatch.comArmata Pharma Shares Up 24% After Positive Cystic Fibrosis Therapeutic Trial DataMarch 6, 2023 | msn.comArmata Surges on Promising Data in Lung InfectionMarch 6, 2023 | msn.comArmata surges 15% as inhaled bacterial infection drug shows promise in lung disorder patientsMarch 6, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)March 6, 2023 | markets.businessinsider.comArmata Pharma Presents Positive Topline Data For Lead Multi-phage Candidate, AP-PA02March 6, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic FibrosisJanuary 10, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLCDecember 22, 2022 | finance.yahoo.comArmata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionDecember 8, 2022 | finance.yahoo.comArmata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 28, 2022 | finance.yahoo.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on BacteriophageNovember 28, 2022 | finance.yahoo.comAfter Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)November 15, 2022 | finance.yahoo.comHere's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom FishingNovember 9, 2022 | finance.yahoo.comArmata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate UpdateSee More Headlines ARMP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARMP Company Calendar Last Earnings5/11/2023Today6/07/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ARMP CUSIPN/A CIKN/A Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees69Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+345.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,920,000.00 Net Margins-841.24% Pretax Margin-841.22% Return on Equity-108.35% Return on Assets-42.80% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual Sales$5.51 million Price / Sales10.30 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.57Miscellaneous Outstanding Shares36,150,000Free Float7,193,000Market Cap$56.76 million OptionableNot Optionable Beta1.17 Key ExecutivesBrian C. VarnumChief Executive Officer & DirectorDuane A. MorrisVice President-OperationsJulianne AverillChief Financial & Accounting OfficerMina PastagiaChief Medical OfficerBryan KadotaniVice President-Program Management & OperationsKey CompetitorsQuince TherapeuticsNASDAQ:QNCXPharmaCyte BiotechOTCMKTS:PMCBTCR2 TherapeuticsNASDAQ:TCRRTaysha Gene TherapiesNASDAQ:TSHAPassage BioNASDAQ:PASGView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 10,500 shares on 5/12/2023Ownership: 0.175%HRT Financial LPSold 11,083 shares on 5/12/2023Ownership: 0.086%Simplex Trading LLCBought 1,000 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions ARMP Stock - Frequently Asked Questions Should I buy or sell Armata Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares. View ARMP analyst ratings or view top-rated stocks. What is Armata Pharmaceuticals' stock price forecast for 2023? 1 brokers have issued 12-month price objectives for Armata Pharmaceuticals' shares. Their ARMP share price forecasts range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 345.9% from the stock's current price. View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts. Are investors shorting Armata Pharmaceuticals? Armata Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 21,900 shares, a drop of 41.8% from the April 30th total of 37,600 shares. Based on an average daily volume of 12,900 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.2% of the company's shares are sold short. View Armata Pharmaceuticals' Short Interest. When is Armata Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ARMP earnings forecast. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.11. The firm earned $0.80 million during the quarter, compared to the consensus estimate of $1.50 million. Armata Pharmaceuticals had a negative net margin of 841.24% and a negative trailing twelve-month return on equity of 108.35%. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD). What is Armata Pharmaceuticals' stock symbol? Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP." Who are Armata Pharmaceuticals' major shareholders? Armata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.17%), HRT Financial LP (0.09%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Armata Pharmaceuticals' stock price today? One share of ARMP stock can currently be purchased for approximately $1.57. How much money does Armata Pharmaceuticals make? Armata Pharmaceuticals (NYSEAMERICAN:ARMP) has a market capitalization of $56.76 million and generates $5.51 million in revenue each year. The company earns $-36,920,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. How can I contact Armata Pharmaceuticals? Armata Pharmaceuticals' mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The official website for the company is www.armatapharma.com. The company can be reached via phone at (310) 655-2928, via email at jallaire@lifesciadvisors.com, or via fax at 310-665-2963. This page (NYSEAMERICAN:ARMP) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.